ECSP17023281A - Inhibidores de mk2 y sus usos - Google Patents

Inhibidores de mk2 y sus usos

Info

Publication number
ECSP17023281A
ECSP17023281A ECIEPI201723281A ECPI201723281A ECSP17023281A EC SP17023281 A ECSP17023281 A EC SP17023281A EC IEPI201723281 A ECIEPI201723281 A EC IEPI201723281A EC PI201723281 A ECPI201723281 A EC PI201723281A EC SP17023281 A ECSP17023281 A EC SP17023281A
Authority
EC
Ecuador
Prior art keywords
inhibitors
compositions
methods
present
provides compounds
Prior art date
Application number
ECIEPI201723281A
Other languages
English (en)
Inventor
Deqiang Niu
Young Ju Kim
S A Edesa
De Frio E Congelaçâo S A Frigocon-Industria
Ji Yun Lee
Joseph John Mcdonald
Russell C Petter
Juswinder Singh
Development Company L P Hewlett­-Packard
Original Assignee
Celgene Car Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Car Llc filed Critical Celgene Car Llc
Publication of ECSP17023281A publication Critical patent/ECSP17023281A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención proporciona compuestos, composiciones de los mismos y métodos para utilizarlos.
ECIEPI201723281A 2014-09-17 2017-04-13 Inhibidores de mk2 y sus usos ECSP17023281A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US201562199927P 2015-07-31 2015-07-31

Publications (1)

Publication Number Publication Date
ECSP17023281A true ECSP17023281A (es) 2017-06-30

Family

ID=55454109

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201723281A ECSP17023281A (es) 2014-09-17 2017-04-13 Inhibidores de mk2 y sus usos

Country Status (30)

Country Link
US (5) US9458175B2 (es)
EP (2) EP3912981A1 (es)
JP (3) JP6556225B2 (es)
KR (1) KR102457848B1 (es)
CN (1) CN106998692B (es)
AU (1) AU2015317741B2 (es)
BR (1) BR112017005266B1 (es)
CA (1) CA2961607C (es)
CL (1) CL2017000576A1 (es)
CO (1) CO2017003279A2 (es)
CY (1) CY1124215T1 (es)
DK (1) DK3193611T3 (es)
EA (1) EA037299B1 (es)
EC (1) ECSP17023281A (es)
ES (1) ES2874561T3 (es)
HR (1) HRP20210529T1 (es)
HU (1) HUE054347T2 (es)
IL (1) IL251051B (es)
LT (1) LT3193611T (es)
MA (1) MA40534B1 (es)
MX (2) MX373341B (es)
PL (1) PL3193611T3 (es)
PT (1) PT3193611T (es)
RS (1) RS62017B1 (es)
SA (1) SA517381115B1 (es)
SG (2) SG10201902326XA (es)
SI (1) SI3193611T1 (es)
SM (1) SMT202100311T1 (es)
TW (1) TWI744217B (es)
WO (1) WO2016044463A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014149164A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
CA2961607C (en) 2014-09-17 2023-03-28 Celgene Car Llc Mk2 inhibitors and uses thereof
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
JP2020514361A (ja) * 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用
WO2018170201A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc Deuterated analogs of mk2 inhibitors and uses thereof
JP7200120B2 (ja) * 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
CN110678178B (zh) * 2017-03-16 2023-10-03 百时美施贵宝公司 Mk2抑制剂的形式和组合物
MX387359B (es) * 2017-03-16 2025-03-18 Bristol Myers Squibb Co Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
EP3860636A4 (en) * 2018-10-02 2022-06-22 Disc Medicine, Inc. MATRIPTASE 2 INHIBITORS AND THEIR USES
CN114364681A (zh) * 2019-05-17 2022-04-15 西建卡尔有限责任公司 治疗mk2介导的病症的方法
US20230130766A1 (en) * 2020-02-14 2023-04-27 Salk Institute For Biological Studies Mono and combination therapies with ulk1/2 inhibitors
US20230087078A1 (en) * 2020-03-02 2023-03-23 Washington University Compositions and methods for the treatment of pancreatic cancer
JP2023536427A (ja) * 2020-07-24 2023-08-25 ブリストル－マイヤーズ スクイブ カンパニー 急性呼吸器障害の治療方法
EP4244341A4 (en) * 2020-11-12 2025-01-15 Akttyva Therapeutics, Inc. Mk2 activating compounds for use in treating vascular leak and endothelial barrier disorders
TW202246282A (zh) 2021-02-01 2022-12-01 美商西建公司 Ｍｋ２抑制劑、其合成及其中間體
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
TW202328141A (zh) * 2021-08-27 2023-07-16 大陸商瑞石生物醫藥有限公司 喹啉并呋喃衍生物及其用途
JP2025503581A (ja) 2022-01-14 2025-02-04 上▲海▼翰森生物医▲薬▼科技有限公司 ピリジン含有多環系誘導体、その製造方法及び応用
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
WO2024092115A2 (en) * 2022-10-27 2024-05-02 Bristol-Myers Squibb Company Mk2 inhibitors and uses thereof
CN120676947A (zh) * 2023-02-07 2025-09-19 细胞基因公司 可用作mk2激酶降解剂的化合物和组合物
WO2024229401A2 (en) * 2023-05-04 2024-11-07 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
WO2025002076A1 (zh) * 2023-06-26 2025-01-02 深圳信立泰药业股份有限公司 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
CA2186371A1 (en) 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
ZA200707482B (en) 2005-02-04 2008-12-31 Senomyx Inc Compounds comprising linked heteroaryl moieties and their use as novel umami flavour modifiers, tastants and taste enhancers for comestible compositions
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
JP2010505961A (ja) 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
AR067535A1 (es) 2007-07-16 2009-10-14 Novartis Ag Derivados de lactama tetraciclicos
CA2703203C (en) 2007-10-22 2015-12-15 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
TWI458721B (zh) 2008-06-27 2014-11-01 Celgene Avilomics Res Inc 雜芳基化合物及其用途
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (en) * 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
CN112029513B (zh) 2012-02-22 2024-02-23 默克专利股份有限公司 液晶介质
US9187453B2 (en) * 2012-03-28 2015-11-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
HK1210696A1 (en) * 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN104981791A (zh) * 2012-09-24 2015-10-14 克莱尔蒙特·斯皮德 移动发送方控制的数据访问和数据删除方法和系统
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
WO2014149164A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
WO2016032882A1 (en) 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
CA2961607C (en) 2014-09-17 2023-03-28 Celgene Car Llc Mk2 inhibitors and uses thereof
MX2017008994A (es) 2015-01-08 2018-09-18 Moerae Matrix Inc Formulacion de peptidos inhibidores mk2.
WO2018170201A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Deuterated analogs of mk2 inhibitors and uses thereof
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
JP2020514361A (ja) 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用
MX387359B (es) 2017-03-16 2025-03-18 Bristol Myers Squibb Co Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.
CN110678178B (zh) 2017-03-16 2023-10-03 百时美施贵宝公司 Mk2抑制剂的形式和组合物
CN114364681A (zh) 2019-05-17 2022-04-15 西建卡尔有限责任公司 治疗mk2介导的病症的方法
JP2023536427A (ja) 2020-07-24 2023-08-25 ブリストル－マイヤーズ スクイブ カンパニー 急性呼吸器障害の治療方法

Also Published As

Publication number Publication date
JP2022078315A (ja) 2022-05-24
US20160075720A1 (en) 2016-03-17
CO2017003279A2 (es) 2017-09-29
CN106998692B (zh) 2020-09-08
MX2017003359A (es) 2017-11-22
US20210053984A1 (en) 2021-02-25
RS62017B1 (sr) 2021-07-30
US9790235B2 (en) 2017-10-17
MX373341B (es) 2020-05-26
CA2961607C (en) 2023-03-28
PL3193611T3 (pl) 2021-10-04
WO2016044463A3 (en) 2016-09-01
NZ730603A (en) 2024-02-23
SG10201902326XA (en) 2019-04-29
TW201617351A (zh) 2016-05-16
IL251051B (en) 2019-11-28
KR20170063734A (ko) 2017-06-08
DK3193611T3 (da) 2021-05-10
EA037299B1 (ru) 2021-03-05
HUE054347T2 (hu) 2021-08-30
ES2874561T3 (es) 2021-11-05
HRP20210529T1 (hr) 2021-08-06
JP2019194236A (ja) 2019-11-07
MA40534B1 (fr) 2021-04-30
CA2961607A1 (en) 2016-03-24
AU2015317741B2 (en) 2020-01-16
EP3193611A2 (en) 2017-07-26
EP3193611A4 (en) 2018-02-28
US11584757B2 (en) 2023-02-21
SA517381115B1 (ar) 2021-03-09
BR112017005266A2 (pt) 2017-12-12
EP3912981A1 (en) 2021-11-24
US9458175B2 (en) 2016-10-04
SG11201701861RA (en) 2017-04-27
MX2020005213A (es) 2020-08-20
LT3193611T (lt) 2021-08-25
CY1124215T1 (el) 2022-05-27
AU2015317741A1 (en) 2017-04-20
WO2016044463A2 (en) 2016-03-24
IL251051A0 (en) 2017-04-30
TWI744217B (zh) 2021-11-01
PT3193611T (pt) 2021-05-28
CL2017000576A1 (es) 2017-12-01
BR112017005266B1 (pt) 2022-11-01
KR102457848B1 (ko) 2022-10-25
MA40534A (fr) 2016-03-24
SI3193611T1 (sl) 2021-08-31
EA201790380A1 (ru) 2017-08-31
SMT202100311T1 (it) 2021-07-12
US10577380B2 (en) 2020-03-03
US20190375762A1 (en) 2019-12-12
US10253040B1 (en) 2019-04-09
EP3193611B1 (en) 2021-03-24
CN106998692A (zh) 2017-08-01
JP7375072B2 (ja) 2023-11-07
JP2017529367A (ja) 2017-10-05
JP6556225B2 (ja) 2019-08-07
US20170114073A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
ECSP17023281A (es) Inhibidores de mk2 y sus usos
CO2018005381A2 (es) Inhibidores éster de acc y usos de los mismos
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
MX380146B (es) Inhibidores mk2 y usos de los mismos.
CL2016001871A1 (es) Anticuerpos humanos para pd-1
CR20150462A (es) Inhibidores de erk y sus usos
ECSP18008905A (es) Tricíclicos sustituidos y método para usarlos.
UY37523A (es) Anticuerpos anti-ox40 y sus usos
MX2018003491A (es) Represores de htt y usos de estos.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
IL248519A0 (en) Bioceramic compositions and biomodulatory uses thereof
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
DK3137605T3 (da) Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
ECSP18049420A (es) Composiciones novedosas, usos y métodos para hacerlas
MX375352B (es) Reguladores de nrf2.
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2017002469A (es) Composiciones de matrices extracelulares.
MX377774B (es) Formulaciones de proteinas.
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
DK2910535T3 (da) Sammensætning til anvendelse af ekspanderet perlit
MX2017013729A (es) Deteccion especifica de isoformas de clusterina.
MX383460B (es) Derivados peptidicos novedosos y sus usos.